Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis
- PMID: 34239046
- DOI: 10.1038/s41391-021-00425-1
Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis
Abstract
Background: Several studies evaluated prostate cancer (PCa) outcomes in Black men on active surveillance (AS); most studies contained few Black men and results were conflicting. We performed a systematic review and meta-analyze of race and outcomes on AS.
Methods: A systematic search was performed for articles of men with Grade Group 1 or 2 (GG1 or GG2) PCa on AS. All studies required race-specific comparative progression data. Progression to treatment, PSA, or biopsy progression were considered and relative risk (RR) estimates of Black men progressing were extracted and pooled using random-effects models. Differences by study-level characteristics were evaluated using subgroup and a cumulative meta-analysis by time.
Results: In total, 12 studies were included (3137 Black and 12,206 non-Black men); eight prospective (27%, n = 4210) and four retrospectives (73%, n = 11,133) cohorts. The overall RR of progression for Black men was 1.62 (95%CI, 1.21-2.17), I2 = 64% (95% CI, 32-80%), (χ2 = 30.23; P = 0.001; τ2 = 0.16). Black men with GG1 PCa alone had a higher pooled progression: RR = 1.81 (95% CI, 1.23-2.68). Including only studies with clinical progression (excluding progression to treatment), potentiated results: RR = 1.82 (95%CI, 1.27-2.60). However, a cumulative meta-analysis demonstrated decreasing pooled effect over time, with contemporary studies after 2019 showing a tempered effect (RR: 1.29, 95% CI: 1.20-1.39).
Conclusions: Many studies attribute racial disparity in PCa to delayed presentation of disease, however, AS is unique since all AS eligible men have a low grade and stage PCa. Our findings suggest Black men may have an increased risk of progression during AS, but the association is not so strong that Black men should be discouraged from undergoing AS. Indeed, contemporary evidence suggests stricter inclusion, better confirmatory testing or better access to care may temper these findings. Importantly, these results utilize self-reported race, a social construct that has many limitations.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Selenium for preventing cancer.Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4. Cochrane Database Syst Rev. 2018. PMID: 29376219 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.Cochrane Database Syst Rev. 2002;(1):CD003506. doi: 10.1002/14651858.CD003506. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2019 Jun 11;6:CD003506. doi: 10.1002/14651858.CD003506.pub2. PMID: 11869665 Updated.
-
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. Cochrane Database Syst Rev. 2021. PMID: 34473343 Free PMC article.
Cited by
-
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016.Prostate Cancer Prostatic Dis. 2025 Jun;28(2):385-393. doi: 10.1038/s41391-024-00822-2. Epub 2024 Mar 30. Prostate Cancer Prostatic Dis. 2025. PMID: 38555410
-
Review of Active Surveillance in Underrepresented and High-Risk Populations: Feasibility and Safety.Curr Urol Rep. 2023 Jul;24(7):307-315. doi: 10.1007/s11934-023-01158-5. Epub 2023 Mar 30. Curr Urol Rep. 2023. PMID: 36995563 Review.
-
Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic Outcomes.Oncologist. 2023 Feb 8;28(2):149-156. doi: 10.1093/oncolo/oyac154. Oncologist. 2023. PMID: 35920550 Free PMC article.
-
Ascertaining provider-level implicit bias in electronic health records with rules-based natural language processing: A pilot study in the case of prostate cancer.PLoS One. 2024 Dec 30;19(12):e0314989. doi: 10.1371/journal.pone.0314989. eCollection 2024. PLoS One. 2024. PMID: 39775249 Free PMC article.
-
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.JAMA Netw Open. 2023 Mar 1;6(3):e231439. doi: 10.1001/jamanetworkopen.2023.1439. JAMA Netw Open. 2023. PMID: 36862409 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous